The Transverse Myelitis Association funds clinical and biomedical research in order to better understand the causes of Transverse Myelitis (including Acute Flaccid Myelitis), Neuromyelitis Optica Spectrum Disorder, MOG Antibody-Associated Disease, Acute Disseminated Encephalitis and Optic Neuritis; and to advance early diagnosis, treatment, and cure. The main output of this research is new knowledge. To ensure this knowledge can be accessed, read, applied, and built upon in fulfillment of our goals, the Transverse Myelitis Association expects its researchers to publish their findings in peer-reviewed journals.
In addition, it is a condition of the Transverse Myelitis Association’s funding that a copy of all funded research outputs, in the form of final, peer-reviewed manuscripts, must be delivered to the Transverse Myelitis Association upon acceptance. These manuscripts will be made publicly available on the Transverse Myelitis Association website no later than 12 months after the official date of publication.
This requirement applies to all Transverse Myelitis Association grants awarded after January 1, 2012.
The policy is developed with the Scholarly Publishing and Academic Resources Coalition (SPARC) and is based on the policy developed by Autism Speaks, with that organization’s permission.